Drugs / DA-2802
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02557594 | Oct → Nov 2015 | — | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02967939 | Mar 2017 → Jan 2019 | chronic hepatitis B virus infection | Dong-A ST Co., Ltd. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DA-2802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02967939 ↗ |
| Route | Oral | “single oral dose” NCT02557594 ↗ |